Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026)
Prothena Corp Public (PRTA) posted quarterly Total Non-Current Liabilities of $4.8 million for Q1 2026, down 48.23% year-over-year from $9.2 million in Q1 2025, and down 13.23% quarter-over-quarter from $5.5 million in Q4 2025.
Analysis
Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Prothena Corp Public's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 48.23% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 48.23% YoY), while the FY2025 annual figure was $5.5 million, down 53.03% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $4.8 million, down from $5.5 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $106.0 million in Q1 2022, with the low at $4.8 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $67.4 million (2023), against an average of $50.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities advanced 7.25% in 2022, then tumbled 88.14% in 2025.
- Prothena Corp Public's Total Non-Current Liabilities stood at $85.8 million in 2022, then slipped by 8.99% to $78.1 million in 2023, then tumbled by 85.05% to $11.7 million in 2024, then sank by 53.03% to $5.5 million in 2025, then decreased by 13.23% to $4.8 million in 2026.
- Business Quant data shows PRTA's Total Non-Current Liabilities at $4.8 million in Q1 2026, $5.5 million in Q4 2025, and $6.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Prothena Corp Public | 506.33 Mn | 218.13 Mn | - | 4.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Mn |
| Mar 31, 2026 | 4.76 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 11.68 Mn |
| Sep 30, 2024 | 14.47 Mn |
| Jun 30, 2024 | 16.90 Mn |
| Mar 31, 2024 | 77.53 Mn |
| Dec 31, 2023 | 78.13 Mn |
| Sep 30, 2023 | 76.32 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.85 Mn |
| Sep 30, 2022 | 99.19 Mn |
| Jun 30, 2022 | 102.18 Mn |
| Mar 31, 2022 | 106.03 Mn |
| Dec 31, 2021 | 109.87 Mn |
| Sep 30, 2021 | 113.03 Mn |